Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.

Autor:	Chahla RE; Ministerio de Salud Pública de Tucumán (SIPROSA). Tucumán, Argentina., Tomas-Grau RH; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., Cazorla SI; Centro de Referencia para Lactobacilos-CERELA (CONICET). Tucumán, Argentina., Ploper D; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., Vera Pingitore E; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., López MA; Laboratorio de Salud Pública (LSP-SIPROSA). Tucumán, Argentina., Aznar P; Laboratorio de Salud Pública (LSP-SIPROSA). Tucumán, Argentina., Alcorta ME; Laboratorio de Salud Pública (LSP-SIPROSA). Tucumán, Argentina., Vélez EMDM; Laboratorio de Salud Pública (LSP-SIPROSA). Tucumán, Argentina., Stagnetto A; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., Ávila CL; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., Maldonado-Galdeano C; Centro de Referencia para Lactobacilos-CERELA (CONICET). Tucumán, Argentina., Socias SB; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., Heinze D; Department of Medicine, Section of Gastroenterology, Center for Regenerative Medicine (CReM), Boston University School of Medicine. Boston, MA, United States., Navarro SA; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina., Llapur CJ; Ministerio de Salud Pública de Tucumán (SIPROSA). Tucumán, Argentina., Costa D; Laboratorio de Salud Pública (LSP-SIPROSA). Tucumán, Argentina., Flores I; Laboratorio de Salud Pública (LSP-SIPROSA). Tucumán, Argentina., Edelstein A; Administración Nacional de Laboratorios e Institutos de Salud (ANLIS), Dr. Carlos G. Malbrán. Buenos Aires, Argentina., Kowdle S; Department of Microbiology at the Icahn School of Medicine at Mount Sinai. New York, NY, United States., Perandones C; Administración Nacional de Laboratorios e Institutos de Salud (ANLIS), Dr. Carlos G. Malbrán. Buenos Aires, Argentina., Lee B; Department of Microbiology at the Icahn School of Medicine at Mount Sinai. New York, NY, United States., Apfelbaum G; Facultad de Medicina, Universidad Nacional de Tucumán (UNT). Tucumán, Argentina., Mostoslavsky R; The Massachusetts General Hospital Cancer Center, Harvard Medical School. Boston, MA, United States., Mostoslavsky G; Department of Medicine, Section of Gastroenterology, Center for Regenerative Medicine (CReM), Boston University School of Medicine. Boston, MA, United States., Perdigón G; Centro de Referencia para Lactobacilos-CERELA (CONICET). Tucumán, Argentina., Chehín RN; Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina.
Jazyk:	angličtina
Zdroj:	Lancet regional health. Americas [Lancet Reg Health Am] 2022 Feb; Vol. 6, pp. 100123. Date of Electronic Publication: 2021 Nov 20.
DOI:	10.1016/j.lana.2021.100123
Abstrakt:	Background: Gam-COVID-Vac (SPUTNIK V) has been granted emergency use authorization in 70 nations and has been administered to millions worldwide. However, there are very few peer-reviewed studies describing its effects. Independent reports regarding safety and effectiveness could accelerate the final approval by the WHO. We aimed to study the long-term humoral immune response in naïve and previously infected volunteers who received SPUTNIK V. Methods: Humoral immune responses, assayed by anti-SARS-CoV-2-spike-RBD IgG ELISA and neutralization assays, were measured in 602 healthcare workers at 0, 14, 28, 60 and 180 days after receiving SPUTNIK V between December 2020 and July 2021 in Tucumán, Argentina. Findings: Seroconversion was detected in 97% of individuals after 28 days post-vaccination (dpv) ( N  = 405). Anti-RBD titers began to decrease after 60 dpv ( N  = 328), but remained detectable in 94% at 90 dpv ( N  = 224). At 180 dpv, anti-RDB titers persisted in 31% ( N  = 146). Previous infection triggered an increased immune response to the first dose and increased neutralization activity against variants of concern (VOC). Second doses in previously infected individuals further increased titers, even 90 dpv ( N  = 75). Basal antibody titers had more influence on post-vaccination anti-RBD responses than the time elapsed between diagnosis and vaccination ( N  = 274). Interpretation: Data presented herein provides essential knowledge regarding the kinetics of antibodies induced by SPUTNIK V up to six months after immunization, and suggests that when considering one-dose vaccination policies for individuals with previous SARS-CoV-2 infection, serological studies to determine basal titers may be important, independent of when diagnosis occurred. Funding: Tucumán Public Health System (SIPROSA), Argentinean National Research Council (CONICET), National University of Tucumán (UNT). Competing Interests: B. L. is a named inventor on a patent filed by the Icahn School of Medicine, which includes the 293T-ACE2-TMPRSS2 (F8–2) cells used for the virus neutralization assay. REC declares being involved in the vaccination process for the Ministry of Health of the Province of Tucumán, Argentina. All other authors report no competing interests. (© 2021 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu